1-4 of 4
Denise Zou
Close
Sort by
Journal Articles

Use of Single-Arm Trials in FDA Approvals of Treatments in Relapsed or Refractory B-Cell Lymphoma

Denise Zou, Eileen Zhang, Sherry Wu, Virgil Rose
Journal: Blood
Blood (2023) 142 (Supplement 1): 7250.
https://doi.org/10.1182/blood-2023-189855
Published: 2023
Journal Articles

Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States

Ha Anh Pham, MSc, Sandra Milev, Shujun Li, Denise Zou, Yannan Hu, PhD, Bart Heeg, PhD, Timothy J Bell, MHA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5852.
https://doi.org/10.1182/blood-2019-122709
Published: 2019
Journal Articles

Budget Impact of First-Line Bosutinib for Chronic Phase Chronic Myeloid Leukemia on a US Health Plan

Verna L Welch, PhD MPH, CPEHR, CPHIMS, Peter Quon, MPH, Denise Zou, Jennifer Uyei, PhD MPH, Sherry Wu, MPH, Ying Xiao, Carla M. Mamolo, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5834.
https://doi.org/10.1182/blood-2018-99-110544
Published: 2018
Journal Articles

Cost-Effectiveness Analysis in Canada of Dasatinib Versus Imatinib for the Treatment of Chronic Myelogenous Leukemia in Patients with Imatinib Resistance.

Jennifer C. Sambrook, M.Sc., Denise Zou, M.Sc., Matthew J. Taylor, Catherine C. Davis, Pharm.D., Alexandre Joyeux, PhD, Adrian R. Levy, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 3328.
https://doi.org/10.1182/blood.V110.11.3328.3328
Published: 2007